ClinicalTrials.gg
CompletedNCT00102713Updated May 21, 2007

A Study for Treatment of Partial Seizures in Children

A Phase 3 interventional study of Divalproex Sodium (Depakote Sprinkle Capsules) in Partial Seizures, sponsored by Abbott. Completed at 10 sites in United States. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2007-05-21.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.

Enrollment
159th of 306
50 · median 56
Started
2005
with 15 others
Phase 3
84 of 395
15 open now
Registered
37th of 395
by date

Among the 395 studies in Seizures with a site in United States, this one is the 159th largest by enrollment of the 306 interventional ones that give a count, is one of 16 that started in 2005, is one of 84 in phase 3, and was the 37th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Seizures with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety profile of the investigational medication, Depakote Sprinkle Capsules, in the treatment of partial seizures in children ages 3-10.

03

Conditions studied

  • Partial Seizures

Browse trials for

Keywords

  • Partial Seizures
04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject has diagnosis of partial seizures with/without secondary generalization, supported by:

  • Observed ictal events consistent with partial seizures with/without secondary generalization; Documented by reliable observers
  • 1 of following 3:

    • EEG at some time in past demonstrating focal abnormalities consistent with partial seizures
    • If the EEG is inconclusive or does not support partial seizures, then an MRI/CT will be done
    • If the MRI/CT fails to support a diagnosis of partial seizures, the subject may still qualify based on the principal Investigator's clinical diagnosis
  • Subject weighs at least 15 kg (33 lbs).
  • Parent/caregiver is able to keep an accurate seizure diary.

Exclusion criteria

Exclusion Criteria:

  • Has had status epilepticus in the past 3 months prior to Screening
  • Has a history of any of: Cardiac (including abnormality on ); Renal; Psychiatric (including psychosurgery); Oncologic; Endocrine; Metabolic; Pancreatic; Hepatic disease (including clinical/serological history of hepatitis); Urea cycle disorder
  • Has: Expanding CNS neoplasm; Active CNS infection; Demyelinating disease; Degenerative neurological disease; Progressive encephalopathy; or any Progressive CNS disease
  • Has count less than or equal to 100,000/mcL
  • Has blood chemistry /AST value(s) greater than or equal to 2 times at screening
  • Requires anticoagulant drug therapy
  • Receiving systemic chemotherapy
  • Requires treatment with aspirin
  • Subject is pregnant
  • Has been on ketogenic diet within 30 days prior to screening
  • Considered by investigator to be non-responder to valproate for treatment of epilepsy (e.g., Despite adequate trial with serum concentrations of 60 mcg/mL or greater, subject continues to have inadequate seizure control)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants
06

What researchers measure

Primary outcomes

  1. Partial Seizure Rate at Week 4

Secondary outcomes

  1. Adverse Events

  2. WASI

  3. WPPSI-III

  4. BASC

  5. UKU-Neurologic Assessment

  6. Vital Signs

  7. Clinical Laboratory Assessments

  8. ECG

  9. PK analysis

07

Study locations

10 sites
  • Neurology Clinic, P.C.
    Northport, Alabama, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Pediatric Epilepsy and Neurology Specialists
    Tampa, Florida, United States
  • Child Neurology Associates, P.C.
    Atlanta, Georgia, United States
  • Akron Children's Hospital
    Akron, Ohio 44308 1062, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Texas Association of Pediatric Neurology, P.A.
    San Antonio, Texas, United States
  • Monarch Medical Research
    Norfolk, Virginia 23510, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298-0211, United States
  • Richard V. Colan, M.D., S.C.
    Milwaukee, Wisconsin 53226, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 21, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00102713
Lead sponsor
Abbott
First posted
Feb 2, 2005
Start date
Feb 2005
Last update
May 21, 2007

Study contacts

Global Medical Information 800-633-9110
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion